Last reviewed · How we verify
Chronic myelomonocytic leukemia
Approved treatments
- Inqovi · Otsuka
Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective. - Vidaza · Bristol-Myers Squibb
Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells. - azacytidine · Assistance Publique Hopitaux De Marseille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic myelomonocytic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Chronic myelomonocytic leukemia treatment landscape brief
- Chronic myelomonocytic leukemia treatment updates RSS
Frequently asked questions about Chronic myelomonocytic leukemia
What drugs treat Chronic myelomonocytic leukemia?
Tracked treatments include Inqovi, Vidaza, azacytidine.
What is the treatment for Chronic myelomonocytic leukemia?
Standard treatment for Chronic myelomonocytic leukemia includes Inqovi, Vidaza, azacytidine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic myelomonocytic leukemia patent cliff · Chronic myelomonocytic leukemia CI report
- Treatment: Inqovi · Otsuka
- Treatment: Vidaza · Bristol-Myers Squibb
- Treatment: azacytidine · Assistance Publique Hopitaux De Marseille
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing